

Special Issue

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Message from the Guest Editor

In solid cancer, treatment performance is improved by multidisciplinary treatment by drug therapy, surgery, and radiation therapy, but it often relapses, and it is difficult to obtain healing for everything. Patient burden is increasing due to the high-powered treatment that progresses year by year, and it is necessary to optimize treatment and improve efficiency. There are few cancer cells circulating in the peripheral blood of patients with solid cancer, which is called the circulating cancer cell circulating tumor cell (CTC). The presence of CTC is considered an indicator of recurrence and poor prognosis, and the loss of CTC may improve the therapeutic effect. CTC can be a criterion for determining whether treatment should be adapted. By moving the primary nest, blood, and bone marrow as cancer stem cells or cancer progenitor cells, and by clarifying the biological properties of CTC, effective treatment methods targeting CTC can be obtained. Against this background, we have configured the Special Issue “From the Laboratory to the Cancer Clinic” for CTC.

Guest Editor

Prof. Dr. Noriyoshi Sawabata
Department of General Thoracic Surgery, Nara Medical University
Hospital, 840 Shijo-Cho, Kashihara, Nara 634-8522, Japan

Deadline for manuscript submissions

closed (20 February 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/56011

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)